Research graph
References from Hypofractionated 44 Gy in 20 fractions versus conventional chemoradiation in cervical cancer: 2-year results of the randomized HYPOCx-iRex trial with an exploratory pooled analysis of a single-institute EMBRACE-II cohort. Local targets link to admitted publications; unresolved targets remain external evidence.
ESGO/ESTRO/ESP Guidelines for the management of patients with cervical cancer – Update 2023
10.1136/ijgc-2023-004429 · 2023 · External reference
MRI-guided adaptive brachytherapy in locally advanced cervical cancer (EMBRACE-I): a multicentre prospective cohort study
10.1016/s1470-2045(20)30753-1 · 2021 · External reference
Clinical outcome comparison between CT-guided versus all MRI-guided scenarios in brachytherapy for cervical cancer: a single-institute experience
10.1016/j.clon.2024.08.003 · 2024 · External reference
Hypofractionated radiotherapy in the real-world setting: an international ESTRO-GIRO survey
10.1016/j.radonc.2021.01.003 · 2021 · External reference
Hypofractionated radiotherapy in treatment of cervical cancer: a systematic review
10.1016/j.ijrobp.2024.07.1529 · 2024 · External reference
Early results of hypofractionated chemoradiation in cervical cancer with 44 Gy/20F VS 45 Gy/25F: a phase II, open-label, randomized controlled trial (HYPOCx-iRex trial)
10.1016/j.clon.2025.103907 · 2025 · External reference
Excess dose-related parameters (Vex, Rex, and iRex): novel predictors and late toxicity correlations in cervical cancer image-guided adaptive brachytherapy
10.5114/jcb.2020.100377 · 2020 · External reference
The EMBRACE II study: the outcome and prospect of two decades of evolution within the GEC-ESTRO GYN working group and the EMBRACE studies
2018 · External reference
Unresolved reference
External reference
Unresolved reference
2021 · External reference
Design of phase II non-inferiority trials
10.1016/j.conctc.2017.04.008 · 2017 · External reference
Concurrent chemotherapy and hypofractionated twice-daily radiotherapy in cervical cancer patients with stage IIIB disease and bilateral parametrial involvement: a phase I-II study
10.1016/j.ijrobp.2004.04.053 · 2004 · External reference
Hypofractionated radiotherapy in carcinoma cervix IIIB: Tata Memorial Hospital experience
2002 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
Calculating and interpreting ICERs and net benefit
10.1007/s40273-020-00914-6 · 2020 · External reference
A comparative analysis of hypofractionated versus conventional radiotherapy for cervical cancer in a resource-limited setting: a prospective study
10.3389/fonc.2025.1552346 · 2025 · External reference
Moderated hypofractionated online adaptive radiotherapy in locally advanced cervical cancer: a prospective 1 clinical trial
10.1016/j.ijrobp.2024.07.014 · 2024 · External reference
Hypofractionated versus standard chemoradiotherapy in the definitive treatment of uterine cervix cancer: interim results of a randomized controlled clinical trial
10.1007/s00432-023-05563-8 · 2024 · External reference
A pilot study of moderately hypo-fractionated whole pelvic radiotherapy with concurrent chemotherapy and image-guided high dose rate brachytherapy for locally advanced cervical carcinoma
10.1016/j.ijrobp.2022.07.500 · 2022 · External reference
A meta-analysis of MRI-based radiomic features for predicting lymph node metastasis in patients with cervical cancer
10.1016/j.ejrad.2022.110243 · 2022 · External reference
An update on the role of MRI in treatment stratification of patients with cervical cancer
10.3390/cancers15205105 · 2023 · External reference
Problems and solutions in IGRT for cervical cancer
10.1016/j.rpor.2018.05.002 · 2018 · External reference
RTT-led IGRT for cervix cancer; training, implementation and validation
10.1016/j.tipsro.2019.10.007 · 2019 · External reference
Weekly image guidance in patients with cervical cancer treated with intensity-modulated radiation therapy: results of a large cohort study
10.1002/cam4.70269 · 2024 · External reference
A prospective single-arm study of daily online adaptive radiation therapy for cervical cancer with reduced planning target volume margin: acute toxicity and dosimetric outcomes
10.1016/j.ijrobp.2025.03.051 · 2025 · External reference
Dose–volume effect relationships for late rectal morbidity in patients treated with chemoradiation and MRI-guided adaptive brachytherapy for locally advanced cervical cancer: results from the prospective multicenter EMBRACE study
10.1016/j.radonc.2016.06.006 · 2016 · External reference
Effect of tumor dose, volume and overall treatment time on local control after radiochemotherapy including MRI guided brachytherapy of locally advanced cervical cancer
10.1016/j.radonc.2016.05.014 · 2016 · External reference
Radiobiological dose calculation parameters for cervix cancer brachytherapy: a systematic review
10.1016/j.brachy.2019.02.007 · 2019 · External reference
2638 EMBRACE II - a multicenter prospective interventional cohort study on IGRT-IMRT+cisplatin+MR-IGABT in locally advanced cervix cancer: overall results
10.1016/s0167-8140(25)01194-6 · 2025 · External reference
Impact of patient selection on real-world outcomes by using the EMBRACE-II treatment protocol in locally advanced cervical cancer
10.1016/j.ijrobp.2025.05.068 · 2025 · External reference
Pembrolizumab with chemoradiotherapy in patients with high-risk locally advanced cervical cancer: final analysis results of the phase 3, randomized, double-blind ENGOT-cx11/GOG-3047/KEYNOTE-A18 study
2025 · External reference
10.1016/s0140-6736(24)01808-7
10.1016/s0140-6736(24)01808-7 · 2024 · External reference
Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial
10.1016/s0140-6736(24)00317-9 · 2024 · External reference
Induction chemotherapy followed by standard chemoradiotherapy versus standard chemoradiotherapy alone in patients with locally advanced cervical cancer (GCIG INTERLACE): an international, multicentre, randomised phase 3 trial
10.1016/s0140-6736(24)01438-7 · 2024 · External reference
2976: CT- VS MRI-based bone marrow dose in CCRT for cervix cancer: a pooled data from 2 prospective trials
10.1016/s0167-8140(24)03072-x · 2024 · External reference
